ArticleThe American journal of pathology2011
Use of gene expression and pathway signatures to characterize the complexity of human melanoma.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging.International journal of molecular sciences · 2024Article
- Article
- Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.Dermatology practical & conceptual · 2023Article
- Hepatocellular carcinoma stage: an almost loss of fatty acid metabolism and gain of glucose metabolic pathways dysregulation.Medical oncology (Northwood, London, England) · 2022Article
- Gene-Interaction-Sensitive enrichment analysis in congenital heart disease.BioData mining · 2022Article
- Clinical size is a poor predictor of invasion in melanoma of the lentigo maligna type.Journal of the American Academy of Dermatology · 2021Article
- Occurrence of differing metabolic dysregulations, a glucose driven and another fatty acid centric in gastric cancer subtypes.Functional & integrative genomics · 2020Article
- Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.Genome biology · 2015Article
- Isolated limb infusion as a model to test new agents to treat metastatic melanoma.Journal of surgical oncology · 2014Review
- Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.Cell cycle (Georgetown, Tex.) · 2014Article
- Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Annals of surgical oncology · 2013Article
- Article
- Genomics screens for metastasis genes.Cancer metastasis reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
A defining characteristic of most human cancers is heterogeneity, resulting from the somatic acquisition of a complex array of genetic and genomic alterations. Dissecting this heterogeneity is critical to developing an understanding of the underlying mechanisms of disease and to paving the way toward personalized treatments of the disease. We used gene expression data sets from the analysis of primary and metastatic melanomas to develop a molecular description of the heterogeneity that characterizes this disease. Unsupervised hierarchical clustering, gene set enrichment analyses, and pathway activity analyses were used to describe the genetic heterogeneity of melanomas. Patterns of gene expression that revealed two distinct classes of primary melanoma, two distinct classes of in-transit melanoma, and at least three subgroups of metastatic melanoma were identified. Expression signatures developed to predict the status of oncogenic signaling pathways were used to explore the biological basis underlying these differential patterns of expression. This analysis of activities revealed unique pathways that distinguished the primary and metastatic subgroups of melanoma. Distinct patterns of gene expression across primary, in-transit, and metastatic melanomas underline the genetic heterogeneity of this disease. This heterogeneity can be described in terms of deregulation of signaling pathways, thus increasing the knowledge of the biological features underlying individual melanomas and potentially directing therapeutic opportunities to individual patients with melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.